Callan JMB Signs Deal to Install Oral Drug Delivery Systems in Texas
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Partnership Announcement: Callan JMB has entered a preliminary agreement with a company that produces an oral drug delivery system to install manufacturing equipment at its cGMP facility in Texas.
CEO Statement: Wayne Williams, CEO of Callan JMB, expressed excitement about the partnership and the potential for advancements in safe and effective oral drug delivery.
Operational Agreements: The two companies are currently negotiating operational agreements related to the installation of the manufacturing technology.
Expansion Goals: This agreement aligns with Callan JMB's objectives to expand into innovative healthcare and wellness technologies.
Analyst Views on CJMB
About CJMB
Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
